Skip to main content
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA — Investor Relations & Filings

Ticker · HYL ISIN · BE0974363955 LEI · 875500LZIWS7QEQE0I73 BR Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2025-12-30 M&A Activity
Country BE Belgium
Listing BR HYL

About Hyloris Pharmaceuticals SA

https://hyloris.com/

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's strategy centers on reformulating and repurposing established drugs to create value-added medicines for patients, healthcare professionals, and payors. By utilizing established regulatory pathways, such as the FDA's 505(b)(2) process, Hyloris aims to reduce development timelines, costs, and risks. The company has built a broad, patented portfolio of product candidates. Its commercialized products include Sotalol IV for the treatment of atrial fibrillation and Maxigesic® IV, a non-opioid for post-operative pain. In addition to its core focus, Hyloris also develops and commercializes high-barrier generic products.

Recent filings

Filing Released Lang Actions
PressRelease_Hyloris_ArborMed_License European rights_Wilson Disease_FINAL_EN_20251230.pdf
M&A Activity Classification · 95% confidence The document is a press release issued by Hyloris Pharmaceuticals announcing a new license agreement with ArborMed for a Wilson's disease therapy. It details the financial terms (upfront payment), the strategic nature of the partnership, and the development pipeline. While it contains 'Regulated Information' and 'Inside Information' headers, it is fundamentally a corporate announcement regarding a business development/licensing deal, which falls under the category of M&A Activity (TAR) as it relates to a strategic partnership and licensing transaction.
2025-12-30 English
PressRelease_Hyloris_ArborMed_License droits européens_Maladie de Wilson_FINAL_FR_20251230.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Hyloris Pharmaceuticals announcing a new licensing agreement with ArborMed for a drug candidate to treat Wilson's disease. It details the financial terms (2 million USD initial payment), the strategic rationale, and the nature of the partnership. This type of corporate announcement regarding business development, partnerships, and licensing agreements is classified as a Regulatory Filing (RNS) in the absence of a more specific category like M&A (which usually refers to corporate takeovers/mergers) or Capital/Financing (which refers to fundraising/debt). Q4 2025
2025-12-30 French
Hyloris_PR_Atomoxetine Outlicensing Rosemont_EN_Final.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Hyloris Pharmaceuticals announcing an exclusive out-licensing and supply agreement with Rosemont Pharmaceuticals for a specific product (Atomoxetine Oral Solution). This type of corporate announcement regarding business partnerships, licensing, and product development strategy is classified as a Regulatory Filing (RNS) in the context of general corporate announcements that do not fit into more specific categories like M&A (which usually implies a merger or acquisition of the company itself) or specific financial reports.
2025-12-29 English
Hyloris_PR_Atomoxetine Outlicensing Rosemont_FR_FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Hyloris Pharmaceuticals announcing a new exclusive licensing and supply agreement with Rosemont Pharmaceuticals for an oral atomoxetine solution in the US market. It details the nature of the partnership, the product's clinical background, and the strategic rationale. As it is a corporate announcement regarding a business partnership/licensing deal, it falls under the category of Regulatory Filings (RNS) as it is a standard regulated information disclosure for a publicly traded company.
2025-12-29 French
PR Hyloris Governance Update EN.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in the company's leadership (appointment of a new CEO) and updates regarding corporate governance. According to the filing definitions, announcements regarding changes in the board of directors or senior management fall under the 'MANG' category.
2025-11-19 English
PR Hyloris Governance Update FR.pdf
Board/Management Information Classification · 100% confidence The document is a press release from Hyloris Pharmaceuticals announcing the appointment of a new sole CEO (Stijn Van Rompay) and updates to the company's governance structure. This falls under the category of management changes and board-related announcements. According to the provided definitions, 'MANG' is the appropriate code for announcements regarding changes in senior management and board structure.
2025-11-19 French

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.